Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1503-1511

  Cen, P ^a   Liu, C ^b   Du, X L ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adverse events; Chemotherapy; Colorectal cancer; Elderly patients; Toxicity

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ABNORMAL LABORATORY RESULT; ACUTE KIDNEY FAILURE; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CARDIOMYOPATHY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COHORT ANALYSIS; COLITIS; COLORECTAL CANCER; COMMUNITY CARE; COMMUNITY LIVING; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DEHYDRATION; DELIRIUM; DERMATITIS; DIARRHEA; DRUG FEVER; FATIGUE; FEMALE; GASTROENTERITIS; GERIATRIC PATIENT; HEART ARRHYTHMIA; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HIGH RISK POPULATION; HUMAN; INFECTION; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT SELECTION; PERIPHERAL NEUROPATHY; POPULATION RESEARCH; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SOCIAL SUPPORT; STOMATITIS; SYMPTOM; THROMBOCYTOPENIA;

EID: 84861760162     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr449     Document Type: Article

References (27)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Popescu RA, Norman A, Ross PJ et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17: 2412-2418.
3. Sargent DJ, Goldberg RM, Jacobson SD et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097.
4. Sundararajan V, Mitra N, Jacobson JS et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002; 136: 349-357.
5. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005; 294: 2703-2711.
6. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091.
7. Folprecht G, Seymour MT, Saltz L et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008; 26: 1443-1451.
8. Cassidy J, Saltz LB, Giantonio BJ et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010; 136: 737-743.
9. Jackson McCleary NM, Green J, Yothers E et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT Database. In ASCO Annual Meeting, Edition 2009.
10. Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
11. Feliu J, Escudero P, Llosa F et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005; 23: 3104-3111.
12. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239.
13. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847.
14. Kabbinavar FF, Hurwitz HI, Yi J et al. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009; 27: 199-205.
15. Allegra CJ, Yothers G, O'Connell MJ et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27: 3385-3390.
16. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
17. Kahn KL, Adams JL, Weeks JC et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA 2010; 303: 1037-1045.
18. Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 1999; 8: 1117-1121.
19. ICD-0-3 SEER SITE/HISTOLOGY VALIDATION LIST. http://seer.cancer.gov/icd-o-3/sitetype.icdo3.d20090401.pdf (1 April 2009, date last accessed).
20. Koroukian SM, Xu F, Bakaki PM et al. Comorbidities, functional limitations, and geriatric syndromes in relation to treatment and survival patterns among elders with colorectal cancer. J Gerontol A Biol Sci Med Sci 2010; 65: 322-329.
21. Meyerhardt JA, Catalano PJ, Haller DG et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003; 21: 433-440.
22. Andre T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21: 2896-2903.
23. Andre T, Quinaux E, Louvet C et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007; 25: 3732-3738.
24. Chau I, Norman AR, Cunningham D et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16: 549-557.
25. Poplin EA, Benedetti JK, Estes NC et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005; 23: 1819-1825.
26. Hu CY, Chan W, Delclos GP, Du XL. Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer. Am J Clin Oncol 2011 Mar 4. [Epub ahead of print].
27. Seymour MT, Thompson LC, Wasan HS et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011; 377: 1749-1759.